NCT07243782Recruiting
Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea
Regulatory Post-Marketing Surveillance to Assess Safety and Effectiveness in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea : a rPMS Study
Source: ClinicalTrials.gov · Last updated 5 Mar 2026
Brief summary (registry, in English)
Regulatory Post-Marketing Surveillance in hidradenitis suppurativa, pediatric plaque psoriasis and JIA treated with Cosentyx®(secukinumab) in Korea
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 76 (estimated)
- First submitted
- 17 Nov 2025
- Start date
- 22 Dec 2025
- Primary completion date
- 15 Jun 2027
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Psoriasis
- NCT number
- NCT07243782
What you commit to
- Study type: Observational
- Planned participants: 76
- From 22 Dec 2025 to the primary completion date, 15 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients who are contraindicated according to national prescribing information
- Patients participating in other interventional clinical trials
Who the study is looking for
- Hidradenitis suppurativa:
- Adults 18 years of age and older with moderate to severe hidradenitis suppurativa who are or will be receiving Cosentyx within the scope of approved indication.
- Patients who have agreed to participate in study (written informed consent)
- Pediatric plaque psoriasis:
- Patients with moderate to severe plaque psoriasis between the ages of 6 and 18 years who are receiving or will receive Cosentyx within the scope of approved indication.
- Patients with patient or guardian consent to participate in study (written informed consent)
- Juvenile idiopathic arthritis:
- Enthesitis related arthritis and juvenile psoriatic arthritis in juvenile idiopathic arthritis category patients with enthesitis related arthritis and juvenile psoriatic arthritis in juvenile idiopathic arthritis category between the ages of 6 and 18 years and are receiving or will receive Cosentyx within the scope of approved indication.
- Patients with patient or guardian consent to participate in study (written informed consent)
Age in the registry: 6 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Seoul | South Korea | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.